ImmunoGen (XTRA:IMU) - Prezzo delle azioni, notizie e analisi

IMU Panoramica delle azioni

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. Maggiori dettagli

IMU analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 48.79% all'anno

Analisi del rischio

Le azioni sono altamente illiquide

Gli azionisti sono stati diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

ImmunoGen, Inc. Concorrenti

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€882.8m

Heidelberg Pharma

XTRA:HPHA

€110.9m

2invest

XTRA:2INV

€64.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per ImmunoGen
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$5.17
Massimo di 52 settimane	US$6.67
Minimo di 52 settimane	US$3.05
Beta	1.06
1Variazione di 1 mese	0%
Variazione a 3 mesi	0%
Variazione di 1 anno	2.16%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	41.90%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	IMU	DE Biotechs	DE Mercato
7D	0%	1.1%	1.3%
1Y	2.2%	-18.5%	7.9%

Ritorno vs Industria: IMU ha superato il German Biotechs che ha restituito -18.5 % nell'ultimo anno.

Rendimento vs Mercato: IMU ha avuto una performance inferiore al mercato German che ha registrato un rendimento 7.9 % nell'ultimo anno.

Volatilità dei prezzi

Is IMU's price volatile compared to industry and market?
IMU volatility
IMU Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: IMU non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di IMU nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1980	106	Mark Enyedy	www.immunogen.com

ImmunoGen, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di ImmunoGen con la sua capitalizzazione di mercato?
IMU statistiche fondamentali
Capitalizzazione di mercato	€1.06b
Guadagni(TTM)	-€193.57m
Ricavi(TTM)	€92.03m

11.6x

Rapporto P/S

-5.5x

Rapporto P/E

IMU è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
IMU Conto economico (TTM)
Ricavi	US$95.61m
Costo del fatturato	US$203.85m
Profitto lordo	-US$108.25m
Altre spese	US$92.85m
Guadagni	-US$201.09m

Ultimi guadagni dichiarati

Sep 30, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.91
Margine lordo	-113.22%
Margine di profitto netto	-210.33%
Rapporto debito/patrimonio netto	0%

Come si è comportato IMU nel lungo periodo?

Vedi performance storica e confronto

IMU Panoramica delle azioni

Premi

Analisi del rischio

ImmunoGen, Inc. Concorrenti

XTRA:BIO3

€1.3b

XTRA:FYB

€882.8m

XTRA:HPHA

€110.9m

XTRA:2INV

€64.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

ImmunoGen, Inc. Announces Mature Data from Forward II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer, Regardless of Platinum Status

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.17 loss in 1Q 2020)

ImmunoGen, Inc. Provides Revenue Guidance for the Year of 2021

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

Executive Officer has left the company

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

New 90-day high: €6.39

ImmunoGen, Inc. Enters into Collaboration and Option Agreement with Subsidiary of Jazz Pharmaceuticals plc

New 90-day high: €5.29

ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

Third quarter 2020 earnings released: US$0.13 loss per share

Revenue beats expectations

New 90-day high: €4.98

ImmunoGen, Inc. Announces Executive Changes, Effective on January 1, 2021

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Announces Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

New 90-day high: €4.63

ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO